{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:33:06Z","timestamp":1780608786157,"version":"3.54.1"},"reference-count":151,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T00:00:00Z","timestamp":1538784000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"INDIAN","award":["SM\/2016-17\/1198\/L"],"award-info":[{"award-number":["SM\/2016-17\/1198\/L"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s11030-018-9878-4","type":"journal-article","created":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T12:40:28Z","timestamp":1538829628000},"page":"509-526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer\u2019s and Parkinson\u2019s diseases"],"prefix":"10.1007","volume":"23","author":[{"given":"Yash Pal","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amruta","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyan","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,6]]},"reference":[{"issue":"8","key":"9878_CR1","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/sj.bjp.0706416","volume":"146","author":"A Gaeta","year":"2005","unstructured":"Gaeta A, Hider RC (2005) The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol 146(8):1041\u20131059. \n                    https:\/\/doi.org\/10.1038\/sj.bjp.0706416","journal-title":"Br J Pharmacol"},{"issue":"1","key":"9878_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1046\/j.1474-9728.2002.00001.x","volume":"1","author":"D Kaur","year":"2002","unstructured":"Kaur D, Andersen JK (2002) Ironing out Parkinson\u2019s disease: is therapeutic treatment with iron chelators a real possibility? Aging Cell 1(1):17\u201321","journal-title":"Aging Cell"},{"key":"9878_CR3","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1196\/annals.1306.025","volume":"1012","author":"MB Youdim","year":"2004","unstructured":"Youdim MB, Stephenson G, Ben Shachar D (2004) Ironing iron out in Parkinson\u2019s disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012:306\u2013325","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"9878_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/s1474-4422(14)70117-6","volume":"13","author":"RJ Ward","year":"2014","unstructured":"Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L (2014) The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 13(10):1045\u20131060. \n                    https:\/\/doi.org\/10.1016\/s1474-4422(14)70117-6","journal-title":"Lancet Neurol"},{"issue":"5","key":"9878_CR5","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1002\/anie.201410456","volume":"54","author":"F Prati","year":"2015","unstructured":"Prati F, De Simone A, Bisignano P, Armirotti A, Summa M, Pizzirani D, Scarpelli R, Perez DI, Andrisano V, Perez-Castillo A, Monti B, Massenzio F, Polito L, Racchi M, Favia AD, Bottegoni G, Martinez A, Bolognesi ML, Cavalli A (2015) Multitarget drug discovery for Alzheimer\u2019s disease: triazinones as BACE-1 and GSK-3beta inhibitors. Angew Chem Int Ed Engl 54(5):1578\u20131582. \n                    https:\/\/doi.org\/10.1002\/anie.201410456","journal-title":"Angew Chem Int Ed Engl"},{"key":"9878_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.arr.2014.03.008","volume":"15","author":"T Silva","year":"2014","unstructured":"Silva T, Reis J, Teixeira J, Borges F (2014) Alzheimer\u2019s disease, enzyme targets and drug discovery struggles: from natural products to drug prototypes. Ageing Res Rev 15:116\u2013145","journal-title":"Ageing Res Rev"},{"issue":"2","key":"9878_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1111\/bcp.12621","volume":"80","author":"S West","year":"2015","unstructured":"West S, Bhugra P (2015) Emerging drug targets for Abeta and tau in Alzheimer\u2019s disease: a systematic review. Br J Clin Pharmacol 80(2):221\u2013234. \n                    https:\/\/doi.org\/10.1111\/bcp.12621","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"9878_CR8","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s13311-014-0335-5","volume":"12","author":"M Shelanski","year":"2015","unstructured":"Shelanski M, Shin W, Aubry S, Sims P, Alvarez MJ, Califano A (2015) A systems approach to drug discovery in Alzheimer\u2019s disease. Neurotherapeutics 12(1):126\u2013131. \n                    https:\/\/doi.org\/10.1007\/s13311-014-0335-5","journal-title":"Neurotherapeutics"},{"issue":"Suppl 1","key":"9878_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/jnc.13425","volume":"139","author":"AA Belaidi","year":"2016","unstructured":"Belaidi AA, Bush AI (2016) Iron neurochemistry in Alzheimer\u2019s disease and Parkinson\u2019s disease: targets for therapeutics. J Neurochem 139(Suppl 1):179\u2013197. \n                    https:\/\/doi.org\/10.1111\/jnc.13425","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"9878_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11010-010-0563-x","volume":"345","author":"K Jomova","year":"2010","unstructured":"Jomova K, Vondrakova D, Lawson M, Valko M (2010) Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 345(1\u20132):91\u2013104. \n                    https:\/\/doi.org\/10.1007\/s11010-010-0563-x","journal-title":"Mol Cell Biochem"},{"issue":"9","key":"9878_CR11","doi-asserted-by":"publisher","first-page":"e1004335","DOI":"10.1371\/journal.ppat.1004335","volume":"10","author":"N Singh","year":"2014","unstructured":"Singh N (2014) The role of iron in prion disease and other neurodegenerative diseases. PLoS Pathog 10(9):e1004335. \n                    https:\/\/doi.org\/10.1371\/journal.ppat.1004335","journal-title":"PLoS Pathog"},{"issue":"8","key":"9878_CR12","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1089\/ars.2012.4931","volume":"20","author":"N Singh","year":"2014","unstructured":"Singh N, Haldar S, Tripathi AK, Horback K, Wong J, Sharma D, Beserra A, Suda S, Anbalagan C, Dev S, Mukhopadhyay CK, Singh A (2014) Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxid Redox Signal 20(8):1324\u20131363. \n                    https:\/\/doi.org\/10.1089\/ars.2012.4931","journal-title":"Antioxid Redox Signal"},{"key":"9878_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1146\/annurev.neuro.28.061604.135718","volume":"28","author":"DJ Moore","year":"2005","unstructured":"Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson\u2019s disease. Annu Rev Neurosci 28:57\u201387. \n                    https:\/\/doi.org\/10.1146\/annurev.neuro.28.061604.135718","journal-title":"Annu Rev Neurosci"},{"issue":"4","key":"9878_CR14","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1046\/j.0022-3042.2001.00742.x","volume":"80","author":"D Berg","year":"2002","unstructured":"Berg D, Gerlach M, Youdim M, Double K, Zecca L, Riederer P, Becker G (2002) Brain iron pathways and their relevance to Parkinson\u2019s disease. J Neurochem 80(4):719\u2013719","journal-title":"J Neurochem"},{"issue":"4","key":"9878_CR15","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00702-016-1508-7","volume":"123","author":"K Li","year":"2016","unstructured":"Li K, Reichmann H (2016) Role of iron in neurodegenerative diseases. J Neural Transm (Vienna, Austria: 1996) 123(4):389\u2013399. \n                    https:\/\/doi.org\/10.1007\/s00702-016-1508-7","journal-title":"J Neural Transm (Vienna, Austria: 1996)"},{"issue":"17","key":"9878_CR16","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.2174\/092986712800609689","volume":"19","author":"RJ Ward","year":"2012","unstructured":"Ward RJ, Dexter DT, Crichton RR (2012) Chelating agents for neurodegenerative diseases. Curr Med Chem 19(17):2760\u20132772","journal-title":"Curr Med Chem"},{"issue":"1","key":"9878_CR17","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41598-017-01402-2","volume":"7","author":"A Martin-Bastida","year":"2017","unstructured":"Martin-Bastida A, Ward RJ, Newbould R, Piccini P, Sharp D, Kabba C, Patel MC, Spino M, Connelly J, Tricta F, Crichton RR, Dexter DT (2017) Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson\u2019s disease. Sci Rep 7(1):1398. \n                    https:\/\/doi.org\/10.1038\/s41598-017-01402-2","journal-title":"Sci Rep"},{"issue":"Pt 6","key":"9878_CR18","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1042\/bst0361304","volume":"36","author":"RC Hider","year":"2008","unstructured":"Hider RC, Ma Y, Molina-Holgado F, Gaeta A, Roy S (2008) Iron chelation as a potential therapy for neurodegenerative disease. Biochem Soc Trans 36(Pt 6):1304\u20131308. \n                    https:\/\/doi.org\/10.1042\/bst0361304","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"9878_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40478-017-0456-2","volume":"5","author":"DI Finkelstein","year":"2017","unstructured":"Finkelstein DI, Billings JL, Adlard PA, Ayton S, Sedjahtera A, Masters CL, Wilkins S, Shackleford DM, Charman SA, Bal W, Zawisza IA, Kurowska E, Gundlach AL, Ma S, Bush AI, Hare DJ, Doble PA, Crawford S, Gautier EC, Parsons J, Huggins P, Barnham KJ, Cherny RA (2017) The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson\u2019s disease. Acta Neuropathol Commun 5(1):53. \n                    https:\/\/doi.org\/10.1186\/s40478-017-0456-2","journal-title":"Acta Neuropathol Commun"},{"key":"9878_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/978-1-60327-029-8_8","volume":"610","author":"G Liu","year":"2010","unstructured":"Liu G, Men P, Perry G, Smith MA (2010) Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol (Clifton, NJ) 610:123\u2013144. \n                    https:\/\/doi.org\/10.1007\/978-1-60327-029-8_8","journal-title":"Methods Mol Biol (Clifton, NJ)"},{"issue":"3","key":"9878_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1039\/C0MT00087F","volume":"3","author":"RC Hider","year":"2011","unstructured":"Hider RC, Roy S, Ma YM, Le Kong X, Preston J (2011) The potential application of iron chelators for the treatment of neurodegenerative diseases. Metallomics 3(3):239\u2013249. \n                    https:\/\/doi.org\/10.1039\/C0MT00087F","journal-title":"Metallomics"},{"key":"9878_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejmech.2018.02.078","volume":"150","author":"D Kumar","year":"2018","unstructured":"Kumar D, Gupta SK, Ganeshpurkar A, Gutti G, Krishnamurthy S, Modi G, Singh SK (2018) Development of Piperazinediones as dual inhibitor for treatment of Alzheimer\u2019s disease. Eur J Med Chem 150:87\u2013101. \n                    https:\/\/doi.org\/10.1016\/j.ejmech.2018.02.078","journal-title":"Eur J Med Chem"},{"issue":"Suppl 1","key":"9878_CR23","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.1016\/s1353-8020(11)70047-5","volume":"18","author":"MB Youdim","year":"2012","unstructured":"Youdim MB (2012) M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Parkinsonism Relat Disord 18(Suppl 1):S151\u2013S154. \n                    https:\/\/doi.org\/10.1016\/s1353-8020(11)70047-5","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"9878_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2174\/0929867324666170518094404","volume":"25","author":"V Lanza","year":"2018","unstructured":"Lanza V, Milardi D, Di Natale G, Pappalardo G (2018) Repurposing of copper(II)-chelating drugs for the treatment of neurodegenerative diseases. Curr Med Chem 25(4):525\u2013539. \n                    https:\/\/doi.org\/10.2174\/0929867324666170518094404","journal-title":"Curr Med Chem"},{"issue":"10","key":"9878_CR25","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1039\/c7mt00156h","volume":"9","author":"V Oliveri","year":"2017","unstructured":"Oliveri V, Lanza V, Milardi D, Viale M, Maric I, Sgarlata C, Vecchio G (2017) Amino- and chloro-8-hydroxyquinolines and their copper complexes as proteasome inhibitors and antiproliferative agents. Metallomics 9(10):1439\u20131446. \n                    https:\/\/doi.org\/10.1039\/c7mt00156h","journal-title":"Metallomics"},{"issue":"1","key":"9878_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jtemb.2013.08.001","volume":"28","author":"P Ramos","year":"2014","unstructured":"Ramos P, Santos A, Pinto NR, Mendes R, Magalhaes T, Almeida A (2014) Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes. J Trace Elem Med Biol 28(1):13\u201317. \n                    https:\/\/doi.org\/10.1016\/j.jtemb.2013.08.001","journal-title":"J Trace Elem Med Biol"},{"issue":"6","key":"9878_CR27","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1046\/j.1471-4159.2001.00186.x","volume":"76","author":"L Zecca","year":"2001","unstructured":"Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D (2001) Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 76(6):1766\u20131773","journal-title":"J Neurochem"},{"issue":"26","key":"9878_CR28","doi-asserted-by":"publisher","first-page":"9843","DOI":"10.1073\/pnas.0403495101","volume":"101","author":"L Zecca","year":"2004","unstructured":"Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA (2004) The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 101(26):9843\u20139848. \n                    https:\/\/doi.org\/10.1073\/pnas.0403495101","journal-title":"Proc Natl Acad Sci USA"},{"key":"9878_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3389\/fnagi.2015.00124","volume":"7","author":"R Bernhardi von","year":"2015","unstructured":"von Bernhardi R, Eugen\u00edn-von Bernhardi L, Eugen\u00edn J (2015) Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci 7:124. \n                    https:\/\/doi.org\/10.3389\/fnagi.2015.00124","journal-title":"Front Aging Neurosci"},{"issue":"3","key":"9878_CR30","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/01.jnen.0000202887.22082.63","volume":"65","author":"JR Conde","year":"2006","unstructured":"Conde JR, Streit WJ (2006) Microglia in the aging brain. J Neuropathol Exp Neurol 65(3):199\u2013203. \n                    https:\/\/doi.org\/10.1097\/01.jnen.0000202887.22082.63","journal-title":"J Neuropathol Exp Neurol"},{"key":"9878_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1750-1326-5-12","volume":"5","author":"X-G Luo","year":"2010","unstructured":"Luo X-G, Ding J-Q, Chen S-D (2010) Microglia in the aging brain: relevance to neurodegeneration. Mol Neurodegener 5:12\u201312. \n                    https:\/\/doi.org\/10.1186\/1750-1326-5-12","journal-title":"Mol Neurodegener"},{"key":"9878_CR32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12979-015-0029-9","volume":"12","author":"M Elahy","year":"2015","unstructured":"Elahy M, Jackaman C, Mamo JCL, Lam V, Dhaliwal SS, Giles C, Nelson D, Takechi R (2015) Blood\u2013brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immun Ageing I A 12:2. \n                    https:\/\/doi.org\/10.1186\/s12979-015-0029-9","journal-title":"Immun Ageing I A"},{"issue":"19","key":"9878_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1136\/jnnp.s1-5.19.195","volume":"5","author":"J Lhermitte","year":"1924","unstructured":"Lhermitte J, Kraus WM, McAlpine D (1924) Original papers: on the occurrence of abnormal deposits of iron in the brain in parkinsonism with special reference to its localisation. J Neurol Psychopathol 5(19):195\u2013208","journal-title":"J Neurol Psychopathol"},{"issue":"1","key":"9878_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005072-196801000-00001","volume":"27","author":"KM Earle","year":"1968","unstructured":"Earle KM (1968) Studies on Parkinson\u2019s disease including X-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 27(1):1\u201314","journal-title":"J Neuropathol Exp Neurol"},{"issue":"Pt 4","key":"9878_CR35","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1093\/brain\/114.4.1953","volume":"114","author":"DT Dexter","year":"1991","unstructured":"Dexter DT, Carayon A, Javoy-Agid F, Agid Y, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson\u2019s disease and other neurodegenerative diseases affecting the basal ganglia. Brain J Neurol 114(Pt 4):1953\u20131975","journal-title":"Brain J Neurol"},{"issue":"1","key":"9878_CR36","first-page":"21","volume":"55","author":"P Riederer","year":"1988","unstructured":"Riederer P, Rausch WD, Schmidt B, Kruzik P, Konradi C, Sofic E, Danielczyk W, Fischer M, Ogris E (1988) Biochemical fundamentals of Parkinson\u2019s disease. Mount Sinai J Med 55(1):21\u201328","journal-title":"Mount Sinai J Med"},{"issue":"2","key":"9878_CR37","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0730-725X(98)00155-6","volume":"17","author":"G Bartzokis","year":"1999","unstructured":"Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciokas LJ, Tishler TA, Marder SR, Mintz J (1999) MRI evaluation of brain iron in earlier- and later-onset Parkinson\u2019s disease and normal subjects. Magn Reson Imaging 17(2):213\u2013222","journal-title":"Magn Reson Imaging"},{"issue":"6","key":"9878_CR38","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1111\/j.1471-4159.2010.07132.x","volume":"118","author":"J Sian-Hulsmann","year":"2011","unstructured":"Sian-Hulsmann J, Mandel S, Youdim MB, Riederer P (2011) The relevance of iron in the pathogenesis of Parkinson\u2019s disease. J Neurochem 118(6):939\u2013957. \n                    https:\/\/doi.org\/10.1111\/j.1471-4159.2010.07132.x","journal-title":"J Neurochem"},{"issue":"1","key":"9878_CR39","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1212\/WNL.45.1.182","volume":"45","author":"G Becker","year":"1995","unstructured":"Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K (1995) Degeneration of substantia nigra in chronic Parkinson\u2019s disease visualized by transcranial color-coded real-time sonography. Neurology 45(1):182\u2013184","journal-title":"Neurology"},{"issue":"2","key":"9878_CR40","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.neuron.2014.12.056","volume":"85","author":"C Iadecola","year":"2015","unstructured":"Iadecola C (2015) Dangerous leaks: blood-brain barrier woes in the aging hippocampus. Neuron 85(2):231\u2013233. \n                    https:\/\/doi.org\/10.1016\/j.neuron.2014.12.056","journal-title":"Neuron"},{"issue":"4","key":"9878_CR41","first-page":"493","volume":"55","author":"K Balveer","year":"2000","unstructured":"Balveer K, Pyar K, Wonke B (2000) Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia 55(4):493\u2013497","journal-title":"Med J Malaysia"},{"issue":"12","key":"9878_CR42","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nm.3407","volume":"19","author":"B Obermeier","year":"2013","unstructured":"Obermeier B, Daneman R, Ransohoff RM (2013) Development, maintenance and disruption of the blood-brain barrier. Nat Med 19(12):1584\u20131596. \n                    https:\/\/doi.org\/10.1038\/nm.3407","journal-title":"Nat Med"},{"key":"9878_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1146\/annurev.nutr.012809.104804","volume":"30","author":"M Wessling-Resnick","year":"2010","unstructured":"Wessling-Resnick M (2010) Iron homeostasis and the inflammatory response. Annu Rev Nutr 30:105\u2013122. \n                    https:\/\/doi.org\/10.1146\/annurev.nutr.012809.104804","journal-title":"Annu Rev Nutr"},{"key":"9878_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2015.09.012","author":"FA Zucca","year":"2015","unstructured":"Zucca FA, Segura-Aguilar J, Ferrari E, Munoz P, Paris I, Sulzer D, Sarna T, Casella L, Zecca L (2015) Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson\u2019s disease. Prog Neurobiol. \n                    https:\/\/doi.org\/10.1016\/j.pneurobio.2015.09.012","journal-title":"Prog Neurobiol"},{"key":"9878_CR45","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/sigtrans.2016.15","volume":"1","author":"S Ayton","year":"2016","unstructured":"Ayton S, Lei P, Mclean C, Bush AI, Finkelstein DI (2016) Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson\u2019s substantia nigra. Signal Transduct Target Therapy 1:16015","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"9878_CR46","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12640-009-9140-z","volume":"19","author":"W Zhang","year":"2011","unstructured":"Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L (2011) Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson\u2019s disease. Neurotox Res 19(1):63\u201372. \n                    https:\/\/doi.org\/10.1007\/s12640-009-9140-z","journal-title":"Neurotox Res"},{"issue":"1\u20134","key":"9878_CR47","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0162-0134(99)00238-X","volume":"79","author":"W Linert","year":"2000","unstructured":"Linert W, Jameson GN (2000) Redox reactions of neurotransmitters possibly involved in the progression of Parkinson\u2019s disease. J Inorg Biochem 79(1\u20134):319\u2013326","journal-title":"J Inorg Biochem"},{"issue":"3","key":"9878_CR48","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/biom3030703","volume":"3","author":"BA Silva","year":"2013","unstructured":"Silva BA, Einarsd\u00f3ttir \u00d3, Fink AL, Uversky VN (2013) Biophysical characterization of \u03b1-synuclein and rotenone interaction. Biomolecules 3(3):703\u2013732. \n                    https:\/\/doi.org\/10.3390\/biom3030703","journal-title":"Biomolecules"},{"issue":"10","key":"9878_CR49","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.4155\/fmc-2017-0016","volume":"9","author":"SK Singh","year":"2017","unstructured":"Singh SK, Dutta A, Modi G (2017) Alpha-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson\u2019s disease. Future Med Chem 9(10):1039\u20131053. \n                    https:\/\/doi.org\/10.4155\/fmc-2017-0016","journal-title":"Future Med Chem"},{"issue":"Pt 5","key":"9878_CR50","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1042\/bst20051106","volume":"33","author":"KE Paleologou","year":"2005","unstructured":"Paleologou KE, Irvine GB, El-Agnaf OM (2005) Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy. Biochem Soc Trans 33(Pt 5):1106\u20131110. \n                    https:\/\/doi.org\/10.1042\/bst20051106","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"9878_CR51","first-page":"24","volume":"36","author":"F Lorenzo Di","year":"2015","unstructured":"Di Lorenzo F (2015) Iron and Parkinson\u2019s disease. Neuro Endocrinol Lett 36(1):24\u201327","journal-title":"Neuro Endocrinol Lett"},{"issue":"30","key":"9878_CR52","doi-asserted-by":"publisher","first-page":"9893","DOI":"10.1021\/ja0618649","volume":"128","author":"A Binolfi","year":"2006","unstructured":"Binolfi A, Rasia RM, Bertoncini CW, Ceolin M, Zweckstetter M, Griesinger C, Jovin TM, Fernandez CO (2006) Interaction of alpha-synuclein with divalent metal ions reveals key differences: a link between structure, binding specificity and fibrillation enhancement. J Am Chem Soc 128(30):9893\u20139901. \n                    https:\/\/doi.org\/10.1021\/ja0618649","journal-title":"J Am Chem Soc"},{"issue":"3","key":"9878_CR53","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1039\/c4mt00339j","volume":"7","author":"E Carboni","year":"2015","unstructured":"Carboni E, Lingor P (2015) Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson\u2019s disease. Metallomics 7(3):395\u2013404. \n                    https:\/\/doi.org\/10.1039\/c4mt00339j","journal-title":"Metallomics"},{"issue":"3","key":"9878_CR54","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.3390\/ijms10031226","volume":"10","author":"D Olivares","year":"2009","unstructured":"Olivares D, Huang X, Branden L, Greig NH, Rogers JT (2009) Physiological and pathological role of alpha-synuclein in Parkinson\u2019s disease through iron mediated oxidative stress; the role of a putative iron-responsive element. Int J Mol Sci 10(3):1226\u20131260. \n                    https:\/\/doi.org\/10.3390\/ijms10031226","journal-title":"Int J Mol Sci"},{"issue":"40","key":"9878_CR55","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai WP, Chilcote TJ (2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281(40):29739\u201329752. \n                    https:\/\/doi.org\/10.1074\/jbc.M600933200","journal-title":"J Biol Chem"},{"issue":"16","key":"9878_CR56","doi-asserted-by":"publisher","first-page":"10992","DOI":"10.1074\/jbc.M709634200","volume":"283","author":"M Kostka","year":"2008","unstructured":"Kostka M, Hogen T, Danzer KM, Levin J, Habeck M, Wirth A, Wagner R, Glabe CG, Finger S, Heinzelmann U, Garidel P, Duan W, Ross CA, Kretzschmar H, Giese A (2008) Single particle characterization of iron-induced pore-forming alpha-synuclein oligomers. J Biol Chem 283(16):10992\u201311003. \n                    https:\/\/doi.org\/10.1074\/jbc.M709634200","journal-title":"J Biol Chem"},{"issue":"4","key":"9878_CR57","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3233\/JAD-161143","volume":"60","author":"S Duijn van","year":"2017","unstructured":"van Duijn S, Bulk M, van Duinen SG, Nabuurs RJA, van Buchem MA, van der Weerd L, Natt\u00e9 R (2017) Cortical iron reflects severity of Alzheimer\u2019s disease. J Alzheimers Dis 60(4):1533\u20131545. \n                    https:\/\/doi.org\/10.3233\/JAD-161143","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"9878_CR58","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/toxsci\/kfv325","volume":"150","author":"ST Szabo","year":"2016","unstructured":"Szabo ST, Harry GJ, Hayden KM, Szabo DT, Birnbaum L (2016) Comparison of metal levels between postmortem brain and ventricular fluid in Alzheimer\u2019s disease and nondemented elderly controls. Toxicol Sci 150(2):292\u2013300. \n                    https:\/\/doi.org\/10.1093\/toxsci\/kfv325","journal-title":"Toxicol Sci"},{"key":"9878_CR59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fnagi.2018.00065","volume":"10","author":"A Ashraf","year":"2018","unstructured":"Ashraf A, Clark M, So P-W (2018) The aging of iron man. Front Aging Neurosci 10:65. \n                    https:\/\/doi.org\/10.3389\/fnagi.2018.00065","journal-title":"Front Aging Neurosci"},{"issue":"Suppl 1","key":"9878_CR60","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1471-4159.2011.07500.x","volume":"120","author":"BR Roberts","year":"2012","unstructured":"Roberts BR, Ryan TM, Bush AI, Masters CL, Duce JA (2012) The role of metallobiology and amyloid-beta peptides in Alzheimer\u2019s disease. J Neurochem 120(Suppl 1):149\u2013166. \n                    https:\/\/doi.org\/10.1111\/j.1471-4159.2011.07500.x","journal-title":"J Neurochem"},{"issue":"7","key":"9878_CR61","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1242\/dmm.019042","volume":"8","author":"S Ott","year":"2015","unstructured":"Ott S, Dziadulewicz N, Crowther DC (2015) Iron is a specific cofactor for distinct oxidation- and aggregation-dependent A\u03b2 toxicity mechanisms in a Drosophila model. Dis Models Mech 8(7):657\u2013667. \n                    https:\/\/doi.org\/10.1242\/dmm.019042","journal-title":"Dis Models Mech"},{"issue":"1","key":"9878_CR62","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s13311-014-0312-z","volume":"12","author":"S Ayton","year":"2015","unstructured":"Ayton S, Lei P, Bush AI (2015) Biometals and their therapeutic implications in Alzheimer\u2019s disease. Neurotherapeutics 12(1):109\u2013120. \n                    https:\/\/doi.org\/10.1007\/s13311-014-0312-z","journal-title":"Neurotherapeutics"},{"issue":"3","key":"9878_CR63","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.0959-9673.2005.00434.x","volume":"86","author":"CJ Maynard","year":"2005","unstructured":"Maynard CJ, Bush AI, Masters CL, Cappai R, Li Q-X (2005) Metals and amyloid-\u03b2 in Alzheimer\u2019s disease. Int J Exp Pathol 86(3):147\u2013159. \n                    https:\/\/doi.org\/10.1111\/j.0959-9673.2005.00434.x","journal-title":"Int J Exp Pathol"},{"key":"9878_CR64","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ejmech.2018.02.035","volume":"148","author":"D Kumar","year":"2018","unstructured":"Kumar D, Ganeshpurkar A, Kumar D, Modi G, Gupta SK, Singh SK (2018) Secretase inhibitors for the treatment of Alzheimer\u2019s disease: long road ahead. Eur J Med Chem 148:436\u2013452. \n                    https:\/\/doi.org\/10.1016\/j.ejmech.2018.02.035","journal-title":"Eur J Med Chem"},{"issue":"2","key":"9878_CR65","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1046\/j.1471-4159.1995.65020710.x","volume":"65","author":"DA Loeffler","year":"1995","unstructured":"Loeffler DA, Connor JR, Juneau PL, Snyder BS, Kanaley L, DeMaggio AJ, Nguyen H, Brickman CM, LeWitt PA (1995) Transferrin and iron in normal, Alzheimer\u2019s disease, and Parkinson\u2019s disease brain regions. J Neurochem 65(2):710\u2013724","journal-title":"J Neurochem"},{"key":"9878_CR66","doi-asserted-by":"publisher","first-page":"6760","DOI":"10.1038\/ncomms7760","volume":"6","author":"S Ayton","year":"2015","unstructured":"Ayton S, Faux NG, Bush AI (2015) Ferritin levels in the cerebrospinal fluid predict Alzheimer\u2019s disease outcomes and are regulated by APOE. Nat Commun 6:6760. \n                    https:\/\/doi.org\/10.1038\/ncomms7760","journal-title":"Nat Commun"},{"key":"9878_CR67","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fnagi.2015.00127","volume":"7","author":"AR White","year":"2015","unstructured":"White AR, Kanninen KM, Crouch PJ (2015) Editorial: metals and neurodegeneration: restoring the balance. Front Aging Neurosci 7:127. \n                    https:\/\/doi.org\/10.3389\/fnagi.2015.00127","journal-title":"Front Aging Neurosci"},{"key":"9878_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccr.2017.06.004","volume":"347","author":"G Grasso","year":"2017","unstructured":"Grasso G, Santoro AM, Lanza V, Sbardella D, Tundo GR, Ciaccio C, Marini S, Coletta M, Milardi D (2017) The double faced role of copper in A\u03b2 homeostasis: a survey on the interrelationship between metal dyshomeostasis, UPS functioning and autophagy in neurodegeneration. Coord Chem Rev 347:1\u201322. \n                    https:\/\/doi.org\/10.1016\/j.ccr.2017.06.004","journal-title":"Coord Chem Rev"},{"issue":"Suppl 1","key":"9878_CR69","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.1016\/s1353-8020(13)70038-5","volume":"20","author":"W Le","year":"2014","unstructured":"Le W (2014) Role of iron in UPS impairment model of Parkinson\u2019s disease. Parkinsonism Relat Disord 20(Suppl 1):S158\u2013S161. \n                    https:\/\/doi.org\/10.1016\/s1353-8020(13)70038-5","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"9878_CR70","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000332954","volume":"20","author":"XP Li","year":"2012","unstructured":"Li XP, Xie WJ, Zhang Z, Kansara S, Jankovic J, Le WD (2012) A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration. Neuro-Signals 20(4):223\u2013236. \n                    https:\/\/doi.org\/10.1159\/000332954","journal-title":"Neuro-Signals"},{"issue":"11","key":"9878_CR71","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1002\/jnr.22405","volume":"88","author":"C Li","year":"2010","unstructured":"Li C, Biswas S, Li X, Dutta AK, Le W (2010) Novel D3 dopamine receptor-preferring agonist D-264: evidence of neuroprotective property in Parkinson\u2019s disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin. J Neurosci Res 88(11):2513\u20132523. \n                    https:\/\/doi.org\/10.1002\/jnr.22405","journal-title":"J Neurosci Res"},{"key":"9878_CR72","doi-asserted-by":"publisher","first-page":"33444","DOI":"10.1038\/srep33444","volume":"6","author":"AM Santoro","year":"2016","unstructured":"Santoro AM, Monaco I, Attanasio F, Lanza V, Pappalardo G, Tomasello MF, Cunsolo A, Rizzarelli E, De Luigi A, Salmona M, Milardi D (2016) Copper(II) ions affect the gating dynamics of the 20S proteasome: a molecular and in cell study. Sci Rep 6:33444. \n                    https:\/\/doi.org\/10.1038\/srep33444","journal-title":"Sci Rep"},{"issue":"9","key":"9878_CR73","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.4155\/fmc.09.121","volume":"1","author":"HC Hatcher","year":"2009","unstructured":"Hatcher HC, Singh RN, Torti FM, Torti SV (2009) Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem 1(9):1643\u20131670","journal-title":"Future Med Chem"},{"key":"9878_CR74","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphar.2013.00167","volume":"4","author":"ZI Cabantchik","year":"2013","unstructured":"Cabantchik ZI, Munnich A, Youdim MB, Devos D (2013) Regional siderosis: a new challenge for iron chelation therapy. Front Pharmacol 4:167. \n                    https:\/\/doi.org\/10.3389\/fphar.2013.00167","journal-title":"Front Pharmacol"},{"key":"9878_CR75","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0020-1693(02)01040-X","volume":"339","author":"F Aouad","year":"2002","unstructured":"Aouad F, Florence A, Zhang Y, Collins F, Henry C, Ward RJ, Crichton RR (2002) Evaluation of new iron chelators and their therapeutic potential. Inorg Chim Acta 339:470\u2013480. \n                    https:\/\/doi.org\/10.1016\/S0020-1693(02)01040-X","journal-title":"Inorg Chim Acta"},{"key":"9878_CR76","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.expneurol.2016.03.016","volume":"280","author":"C Guo","year":"2016","unstructured":"Guo C, Hao LJ, Yang ZH, Chai R, Zhang S, Gu Y, Gao HL, Zhong ML, Wang T, Li JY, Wang ZY (2016) Deferoxamine-mediated up-regulation of HIF-1alpha prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice. Exp Neurol 280:13\u201323. \n                    https:\/\/doi.org\/10.1016\/j.expneurol.2016.03.016","journal-title":"Exp Neurol"},{"issue":"2\u20133","key":"9878_CR77","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000065700","volume":"24","author":"P Sangchot","year":"2002","unstructured":"Sangchot P, Sharma S, Chetsawang B, Porter J, Govitrapong P, Ebadi M (2002) Deferoxamine attenuates iron-induced oxidative stress and prevents mitochondrial aggregation and alpha-synuclein translocation in SK-N-SH cells in culture. Dev Neurosci 24(2\u20133):143\u2013153. \n                    https:\/\/doi.org\/10.1159\/000065700","journal-title":"Dev Neurosci"},{"issue":"5","key":"9878_CR78","doi-asserted-by":"publisher","first-page":"972S","DOI":"10.1093\/ajcn\/67.5.972S","volume":"67","author":"ZL Harris","year":"1998","unstructured":"Harris ZL, Klomp L, Gitlin JD (1998) Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 67(5):972S\u2013977S","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"9878_CR79","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/ars.2013.5593","volume":"21","author":"D Devos","year":"2014","unstructured":"Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garcon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonniere B, Strubi-Vuillaume I, Zahr N, Destee A, Corvol JC, Poltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R (2014) Targeting chelatable iron as a therapeutic modality in Parkinson\u2019s disease. Antioxid Redox Signal 21(2):195\u2013210. \n                    https:\/\/doi.org\/10.1089\/ars.2013.5593","journal-title":"Antioxid Redox Signal"},{"issue":"6","key":"9878_CR80","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.neuint.2006.04.015","volume":"49","author":"H Jiang","year":"2006","unstructured":"Jiang H, Luan Z, Wang J, Xie J (2006) Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int 49(6):605\u2013609. \n                    https:\/\/doi.org\/10.1016\/j.neuint.2006.04.015","journal-title":"Neurochem Int"},{"issue":"9","key":"9878_CR81","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.4155\/fmc.09.121","volume":"1","author":"HC Hatcher","year":"2009","unstructured":"Hatcher HC, Singh RN, Torti FM, Torti SV (2009) Synthetic and natural iron chelators: therapeutic potential and clinical use. Future Med Chem 1(9):1643\u20131670. \n                    https:\/\/doi.org\/10.4155\/fmc.09.121","journal-title":"Future Med Chem"},{"key":"9878_CR82","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jtemb.2016.03.010","volume":"38","author":"P Dusek","year":"2016","unstructured":"Dusek P, Schneider SA, Aaseth J (2016) Iron chelation in the treatment of neurodegenerative diseases. J Trace Elem Med Biol 38:81\u201392","journal-title":"J Trace Elem Med Biol"},{"issue":"4","key":"9878_CR83","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1124\/pr.57.4.2","volume":"57","author":"DS Kalinowski","year":"2005","unstructured":"Kalinowski DS, Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57(4):547\u2013583. \n                    https:\/\/doi.org\/10.1124\/pr.57.4.2","journal-title":"Pharmacol Rev"},{"issue":"12","key":"9878_CR84","first-page":"1423","volume":"88","author":"A Kattamis","year":"2003","unstructured":"Kattamis A, Kassou C, Berdousi H, Ladis V, Papassotiriou I, Kattamis C (2003) Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion. Haematologica 88(12):1423\u20131425","journal-title":"Haematologica"},{"key":"9878_CR85","doi-asserted-by":"publisher","DOI":"10.1042\/BST0361304","volume-title":"Iron chelation as a potential therapy for neurodegenerative disease","author":"RC Hider","year":"2008","unstructured":"Hider RC, Ma Y, Molina-Holgado F, Gaeta A, Roy S (2008) Iron chelation as a potential therapy for neurodegenerative disease. Portland Press Limited, London"},{"issue":"3","key":"9878_CR86","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0896-6273(01)00317-8","volume":"30","author":"RA Cherny","year":"2001","unstructured":"Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y-S (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits \u03b2-amyloid accumulation in Alzheimer\u2019s disease transgenic mice. Neuron 30(3):665\u2013676","journal-title":"Neuron"},{"issue":"1","key":"9878_CR87","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1021\/acschemneuro.5b00253","volume":"7","author":"DI Finkelstein","year":"2016","unstructured":"Finkelstein DI, Hare DJ, Billings JL, Sedjahtera A, Nurjono M, Arthofer E, George S, Culvenor JG, Bush AI, Adlard PA (2016) Clioquinol improves cognitive, motor function, and microanatomy of the alpha-synuclein hA53T transgenic mice. ACS Chem Neurosci 7(1):119\u2013129. \n                    https:\/\/doi.org\/10.1021\/acschemneuro.5b00253","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"9878_CR88","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/S0896-6273(03)00126-0","volume":"37","author":"D Kaur","year":"2003","unstructured":"Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boonplueang R, Viswanath V, Jacobs R, Yang L, Beal MF, DiMonte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, Andersen JK (2003) Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson\u2019s disease. Neuron 37(6):899\u2013909","journal-title":"Neuron"},{"issue":"1","key":"9878_CR89","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0022-510X(99)00297-X","volume":"173","author":"MS Yassin","year":"2000","unstructured":"Yassin MS, Ekblom J, Xilinas M, Gottfries CG, Oreland L (2000) Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci 173(1):40\u201344","journal-title":"J Neurol Sci"},{"issue":"2","key":"9878_CR90","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nm.2613","volume":"18","author":"P Lei","year":"2012","unstructured":"Lei P, Ayton S, Finkelstein DI, Spoerri L, Ciccotosto GD, Wright DK, Wong BX, Adlard PA, Cherny RA, Lam LQ, Roberts BR, Volitakis I, Egan GF, McLean CA, Cappai R, Duce JA, Bush AI (2012) Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med 18(2):291\u2013295. \n                    https:\/\/doi.org\/10.1038\/nm.2613","journal-title":"Nat Med"},{"issue":"8","key":"9878_CR91","doi-asserted-by":"publisher","first-page":"685","DOI":"10.2174\/156720510793611628","volume":"7","author":"I Gozes","year":"2010","unstructured":"Gozes I (2010) Tau pathology and future therapeutics. Curr Alzheimer Res 7(8):685\u2013696","journal-title":"Curr Alzheimer Res"},{"key":"9878_CR92","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.nbd.2015.03.015","volume":"81","author":"P Lei","year":"2015","unstructured":"Lei P, Ayton S, Appukuttan AT, Volitakis I, Adlard PA, Finkelstein DI, Bush AI (2015) Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiol Dis 81:168\u2013175. \n                    https:\/\/doi.org\/10.1016\/j.nbd.2015.03.015","journal-title":"Neurobiol Dis"},{"issue":"10\u201311","key":"9878_CR93","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00702-004-0143-x","volume":"111","author":"MB Youdim","year":"2004","unstructured":"Youdim MB, Fridkin M, Zheng H (2004) Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson\u2019s disease and other neurodegenerative diseases. J Neural Transm (Vienna, Austria: 1996) 111(10\u201311):1455\u20131471. \n                    https:\/\/doi.org\/10.1007\/s00702-004-0143-x","journal-title":"J Neural Transm (Vienna, Austria: 1996)"},{"issue":"1","key":"9878_CR94","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1471-4159.2005.03340.x","volume":"95","author":"H Zheng","year":"2005","unstructured":"Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95(1):68\u201378. \n                    https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03340.x","journal-title":"J Neurochem"},{"issue":"2","key":"9878_CR95","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.mad.2004.08.023","volume":"126","author":"MB Youdim","year":"2005","unstructured":"Youdim MB, Fridkin M, Zheng H (2005) Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Mech Ageing Dev 126(2):317\u2013326. \n                    https:\/\/doi.org\/10.1016\/j.mad.2004.08.023","journal-title":"Mech Ageing Dev"},{"issue":"2","key":"9878_CR96","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","volume":"132","author":"MB Youdim","year":"2001","unstructured":"Youdim MB, Gross A, Finberg JP (2001) Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132(2):500\u2013506. \n                    https:\/\/doi.org\/10.1038\/sj.bjp.0703826","journal-title":"Br J Pharmacol"},{"issue":"1","key":"9878_CR97","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1471-4159.2005.03341.x","volume":"95","author":"S Gal","year":"2005","unstructured":"Gal S, Zheng H, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 95(1):79\u201388. \n                    https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03341.x","journal-title":"J Neurochem"},{"key":"9878_CR98","first-page":"447","volume":"70","author":"S Gal","year":"2006","unstructured":"Gal S, Fridkin M, Amit T, Zheng H, Youdim MB (2006) M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson\u2019s disease. J Neural Transm Suppl 70:447\u2013456","journal-title":"J Neural Transm Suppl"},{"issue":"1","key":"9878_CR99","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s12640-009-9070-9","volume":"17","author":"S Gal","year":"2010","unstructured":"Gal S, Zheng H, Fridkin M, Youdim MB (2010) Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 17(1):15\u201327. \n                    https:\/\/doi.org\/10.1007\/s12640-009-9070-9","journal-title":"Neurotox Res"},{"issue":"1","key":"9878_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5607\/en.2013.22.1.1","volume":"22","author":"MBH Youdim","year":"2013","unstructured":"Youdim MBH (2013) Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and M30 derived from rasagiline. Exp Neurobiol 22(1):1\u201310. \n                    https:\/\/doi.org\/10.5607\/en.2013.22.1.1","journal-title":"Exp Neurobiol"},{"issue":"3","key":"9878_CR101","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.bmc.2004.10.037","volume":"13","author":"H Zheng","year":"2005","unstructured":"Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, Fridkin M (2005) Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer\u2019s, Parkinson\u2019s, and other neurodegenerative diseases. Bioorg Med Chem 13(3):773\u2013783","journal-title":"Bioorg Med Chem"},{"key":"9878_CR102","doi-asserted-by":"publisher","first-page":"CD005380","DOI":"10.1002\/14651858.CD005380.pub4","volume":"5","author":"EL Sampson","year":"2012","unstructured":"Sampson EL, Jenagaratnam L, McShane R (2012) Metal protein attenuating compounds for the treatment of Alzheimer\u2019s dementia. Cochrane Database Syst Rev 5:CD005380\u2013CD005380. \n                    https:\/\/doi.org\/10.1002\/14651858.CD005380.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"9878_CR103","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.neuron.2008.06.018","volume":"59","author":"PA Adlard","year":"2008","unstructured":"Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K (2008) Rapid restoration of cognition in Alzheimer\u2019s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial A\u03b2. Neuron 59(1):43\u201355","journal-title":"Neuron"},{"issue":"9","key":"9878_CR104","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/s1474-4422(08)70167-4","volume":"7","author":"L Lannfelt","year":"2008","unstructured":"Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer\u2019s disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7(9):779\u2013786. \n                    https:\/\/doi.org\/10.1016\/s1474-4422(08)70167-4","journal-title":"Lancet Neurol"},{"issue":"4","key":"9878_CR105","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.bbrc.2015.06.014","volume":"463","author":"NP Mena","year":"2015","unstructured":"Mena NP, Garc\u00eda-Beltr\u00e1n O, Lourido F, Urrutia PJ, Mena R, Castro-Castillo V, Cassels BK, N\u00fa\u00f1ez MT (2015) The novel mitochondrial iron chelator 5-((methylamino) methyl)-8-hydroxyquinoline protects against mitochondrial-induced oxidative damage and neuronal death. Biochem Biophys Res Commun 463(4):787\u2013792","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"9878_CR106","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccr.2011.08.008","volume":"256","author":"MA Santos","year":"2012","unstructured":"Santos MA, Marques SM, Chaves S (2012) Hydroxypyridinones as \u201cprivileged\u201d chelating structures for the design of medicinal drugs. Coord Chem Rev 256(1):240\u2013259","journal-title":"Coord Chem Rev"},{"issue":"17","key":"9878_CR107","doi-asserted-by":"publisher","first-page":"6058","DOI":"10.1039\/c3dt50406a","volume":"42","author":"A Nunes","year":"2013","unstructured":"Nunes A, Marques SM, Quintanova C, Silva DF, Cardoso SM, Chaves S, Santos MA (2013) Multifunctional iron-chelators with protective roles against neurodegenerative diseases. Dalton Trans 42(17):6058\u20136073","journal-title":"Dalton Trans"},{"issue":"3","key":"9878_CR108","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/j.bmc.2010.12.007","volume":"19","author":"A Gaeta","year":"2011","unstructured":"Gaeta A, Molina-Holgado F, Kong XL, Salvage S, Fakih S, Francis PT, Williams RJ, Hider RC (2011) Synthesis, physical\u2013chemical characterisation and biological evaluation of novel 2-amido-3-hydroxypyridin-4 (1H)-ones: iron chelators with the potential for treating Alzheimer\u2019s disease. Bioorg Med Chem 19(3):1285\u20131297","journal-title":"Bioorg Med Chem"},{"issue":"21","key":"9878_CR109","doi-asserted-by":"publisher","first-page":"6371","DOI":"10.1039\/c2dt12159j","volume":"41","author":"T Zhou","year":"2012","unstructured":"Zhou T, Ma Y, Kong X, Hider RC (2012) Design of iron chelators with therapeutic application. Dalton Trans (Cambridge, England: 2003) 41(21):6371\u20136389. \n                    https:\/\/doi.org\/10.1039\/c2dt12159j","journal-title":"Dalton Trans (Cambridge, England: 2003)"},{"issue":"6","key":"9878_CR110","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1021\/ja00032a043","volume":"114","author":"S Konetschny-Rapp","year":"1992","unstructured":"Konetschny-Rapp S, Jung G, Raymond KN, Meiwes J, Zaehner H (1992) Solution thermodynamics of the ferric complexes of new desferrioxamine siderophores obtained by directed fermentation. J Am Chem Soc 114(6):2224\u20132230. \n                    https:\/\/doi.org\/10.1021\/ja00032a043","journal-title":"J Am Chem Soc"},{"issue":"5","key":"9878_CR111","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1039\/C4MT00326H","volume":"7","author":"DG Workman","year":"2015","unstructured":"Workman DG, Tsatsanis A, Lewis FW, Boyle JP, Mousadoust M, Hettiarachchi NT, Hunter M, Peers CS, T\u00e9tard D, Duce JA (2015) Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson\u2019s with novel 1-hydroxypyridin-2-one metal chelators. Metallomics 7(5):867\u2013876","journal-title":"Metallomics"},{"issue":"2","key":"9878_CR112","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0014-5793(79)80111-8","volume":"97","author":"P Ponka","year":"1979","unstructured":"Ponka P, Borova J, Neuwirt J, Fuchs O (1979) Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 97(2):317\u2013321","journal-title":"FEBS Lett"},{"issue":"1","key":"9878_CR113","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1196\/annals.1306.026","volume":"1012","author":"DR Richardson","year":"2004","unstructured":"Richardson DR (2004) Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann N Y Acad Sci 1012(1):326\u2013341","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"9878_CR114","doi-asserted-by":"publisher","first-page":"150","DOI":"10.2174\/157340708786305952","volume":"4","author":"CA Perez","year":"2008","unstructured":"Perez CA, Tong Y, Guo M (2008) Iron chelators as potential therapeutic agents for Parkinson\u2019s disease. Curr Bioact Compd 4(3):150\u2013158","journal-title":"Curr Bioact Compd"},{"issue":"38","key":"9878_CR115","doi-asserted-by":"publisher","first-page":"12424","DOI":"10.1021\/ja064806w","volume":"128","author":"LK Charkoudian","year":"2006","unstructured":"Charkoudian LK, Pham DM, Franz KJ (2006) A pro-chelator triggered by hydrogen peroxide inhibits iron-promoted hydroxyl radical formation. J Am Chem Soc 128(38):12424\u201312425","journal-title":"J Am Chem Soc"},{"issue":"25","key":"9878_CR116","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1002\/anie.200604859","volume":"46","author":"Y Wei","year":"2007","unstructured":"Wei Y, Guo M (2007) Hydrogen peroxide triggered prochelator activation, subsequent metal chelation, and attenuation of the fenton reaction. Angew Chem Int Ed 46(25):4722\u20134725","journal-title":"Angew Chem Int Ed"},{"issue":"8","key":"9878_CR117","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1021\/cn500084x","volume":"5","author":"G Modi","year":"2014","unstructured":"Modi G, Voshavar C, Gogoi S, Shah M, Antonio T, Reith MEA, Dutta AK (2014) Multifunctional D2\/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates. ACS Chem Neurosci 5(8):700\u2013717. \n                    https:\/\/doi.org\/10.1021\/cn500084x","journal-title":"ACS Chem Neurosci"},{"key":"9878_CR118","doi-asserted-by":"publisher","first-page":"38510","DOI":"10.1038\/srep38510","volume":"6","author":"D Yedlapudi","year":"2016","unstructured":"Yedlapudi D, Joshi GS, Luo D, Todi SV, Dutta AK (2016) Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Sci Rep 6:38510. \n                    https:\/\/doi.org\/10.1038\/srep38510","journal-title":"Sci Rep"},{"issue":"1","key":"9878_CR119","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/jnc.12767","volume":"131","author":"M Shah","year":"2014","unstructured":"Shah M, Rajagopalan S, Xu L, Voshavar C, Shurubor Y, Beal F, Andersen JK, Dutta AK (2014) The high-affinity D2\/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson\u2019s disease. J Neurochem 131(1):74\u201385. \n                    https:\/\/doi.org\/10.1111\/jnc.12767","journal-title":"J Neurochem"},{"issue":"10","key":"9878_CR120","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1021\/cn400106n","volume":"4","author":"S Santra","year":"2013","unstructured":"Santra S, Xu L, Shah M, Johnson M, Dutta A (2013) D-512 and D-440 as novel multifunctional dopamine agonists: characterization of neuroprotection properties and evaluation of in vivo efficacy in a Parkinson\u2019s disease animal model. ACS Chem Neurosci 4(10):1382\u20131392. \n                    https:\/\/doi.org\/10.1021\/cn400106n","journal-title":"ACS Chem Neurosci"},{"issue":"12","key":"9878_CR121","doi-asserted-by":"publisher","first-page":"5826","DOI":"10.1021\/jm300268s","volume":"55","author":"M Johnson","year":"2012","unstructured":"Johnson M, Antonio T, Reith MEA, Dutta AK (2012) Structure-activity-relationship study of N(6)-(2(4-(1H-indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2\/D3 agonist and their pharmacological characterization. J Med Chem 55(12):5826\u20135840. \n                    https:\/\/doi.org\/10.1021\/jm300268s","journal-title":"J Med Chem"},{"issue":"3","key":"9878_CR122","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1021\/jm901184n","volume":"53","author":"B Ghosh","year":"2010","unstructured":"Ghosh B, Antonio T, Zhen J, Kharkar P, Reith MEA, Dutta AK (2010) Development of (S)-N(6)-(2-(4-(Isoquinolin-1-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson\u2019s disease animal models. J Med Chem 53(3):1023. \n                    https:\/\/doi.org\/10.1021\/jm901184n","journal-title":"J Med Chem"},{"issue":"5","key":"9878_CR123","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1021\/jm901618d","volume":"53","author":"B Ghosh","year":"2010","unstructured":"Ghosh B, Antonio T, Reith MEA, Dutta AK (2010) Discovery of 4-(4-(2-((5-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)-ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2\/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson\u2019s Disease. J Med Chem 53(5):2114\u20132125. \n                    https:\/\/doi.org\/10.1021\/jm901618d","journal-title":"J Med Chem"},{"issue":"6","key":"9878_CR124","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/cmdc.201100140","volume":"6","author":"S Gogoi","year":"2011","unstructured":"Gogoi S, Antonio T, Rajagopalan S, Reith M, Andersen J, Dutta AK (2011) Dopamine D(2)\/D(3) agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson\u2019s disease. ChemMedChem 6(6):991\u2013995. \n                    https:\/\/doi.org\/10.1002\/cmdc.201100140","journal-title":"ChemMedChem"},{"issue":"4","key":"9878_CR125","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1021\/acschemneuro.6b00356","volume":"8","author":"B Das","year":"2017","unstructured":"Das B, Kandegedara A, Xu L, Antonio T, Stemmler T, Reith MEA, Dutta AK (2017) A novel iron(II) preferring dopamine agonist chelator as potential symptomatic and neuroprotective therapeutic agent for Parkinson\u2019s disease. ACS Chem Neurosci 8(4):723\u2013730. \n                    https:\/\/doi.org\/10.1021\/acschemneuro.6b00356","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"9878_CR126","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ejphar.2006.06.025","volume":"545","author":"C Ramassamy","year":"2006","unstructured":"Ramassamy C (2006) Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 545(1):51\u201364. \n                    https:\/\/doi.org\/10.1016\/j.ejphar.2006.06.025","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"9878_CR127","doi-asserted-by":"publisher","first-page":"7792","DOI":"10.3390\/molecules15117792","volume":"15","author":"NA Kelsey","year":"2010","unstructured":"Kelsey NA, Wilkins HM, Linseman DA (2010) Nutraceutical antioxidants as novel neuroprotective agents. Molecules 15(11):7792\u20137814","journal-title":"Molecules"},{"key":"9878_CR128","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1039\/b705136k","volume":"43","author":"M Guo","year":"2007","unstructured":"Guo M, Perez C, Wei Y, Rapoza E, Su G, Bou-Abdallah F, Chasteen ND (2007) Iron-binding properties of plant phenolics and cranberry\u2019s bio-effects. Dalton Trans (Cambridge, England: 2003) 43:4951\u20134961. \n                    https:\/\/doi.org\/10.1039\/b705136k","journal-title":"Dalton Trans (Cambridge, England: 2003)"},{"issue":"10","key":"9878_CR129","doi-asserted-by":"publisher","first-page":"e0165575","DOI":"10.1371\/journal.pone.0165575","volume":"11","author":"SA Cherrak","year":"2016","unstructured":"Cherrak SA, Mokhtari-Soulimane N, Berroukeche F, Bensenane B, Cherbonnel A, Merzouk H, Elhabiri M (2016) In vitro antioxidant versus metal ion chelating properties of flavonoids: a structure-activity investigation. PLoS ONE 11(10):e0165575. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0165575","journal-title":"PLoS ONE"},{"key":"9878_CR130","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.freeradbiomed.2013.01.017","volume":"62","author":"O Weinreb","year":"2013","unstructured":"Weinreb O, Mandel S, Youdim MB, Amit T (2013) Targeting dysregulation of brain iron homeostasis in Parkinson\u2019s disease by iron chelators. Free Radic Biol Med 62:52\u201364. \n                    https:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.01.017","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"9878_CR131","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1878-5085-4-5","volume":"4","author":"A M\u00e4hler","year":"2013","unstructured":"M\u00e4hler A, Mandel S, Lorenz M, Ruegg U, Wanker EE, Boschmann M, Paul F (2013) Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases? EPMA J 4(1):5\u20135. \n                    https:\/\/doi.org\/10.1186\/1878-5085-4-5","journal-title":"EPMA J"},{"key":"9878_CR132","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.foodchem.2015.11.118","volume":"199","author":"S Chan","year":"2016","unstructured":"Chan S, Kantham S, Rao VM, Palanivelu MK, Pham HL, Shaw PN, McGeary RP, Ross BP (2016) Metal chelation, radical scavenging and inhibition of Abeta(4)(2) fibrillation by food constituents in relation to Alzheimer\u2019s disease. Food Chem 199:185\u2013194. \n                    https:\/\/doi.org\/10.1016\/j.foodchem.2015.11.118","journal-title":"Food Chem"},{"issue":"1","key":"9878_CR133","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12937-016-0179-4","volume":"15","author":"NA Singh","year":"2016","unstructured":"Singh NA, Mandal AK, Khan ZA (2016) Potential neuroprotective properties of epigallocatechin-3-gallate (EGCG). Nutr J 15(1):60. \n                    https:\/\/doi.org\/10.1186\/s12937-016-0179-4","journal-title":"Nutr J"},{"key":"9878_CR134","doi-asserted-by":"publisher","first-page":"843906","DOI":"10.1155\/2015\/843906","volume":"2015","author":"D Chen","year":"2015","unstructured":"Chen D, Kanthasamy AG, Reddy MB (2015) EGCG protects against 6-OHDA-induced neurotoxicity in a cell culture model. Parkinson\u2019s Dis 2015:843906. \n                    https:\/\/doi.org\/10.1155\/2015\/843906","journal-title":"Parkinson\u2019s Dis"},{"issue":"7","key":"9878_CR135","doi-asserted-by":"publisher","first-page":"e102900","DOI":"10.1371\/journal.pone.0102900","volume":"9","author":"M Lesjak","year":"2014","unstructured":"Lesjak M, Hoque R, Balesaria S, Skinner V, Debnam ES, Srai SK, Sharp PA (2014) Quercetin inhibits intestinal iron absorption and ferroportin transporter expression in vivo and in vitro. PLoS ONE 9(7):e102900. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0102900","journal-title":"PLoS ONE"},{"issue":"17","key":"9878_CR136","doi-asserted-by":"publisher","first-page":"6343","DOI":"10.1021\/jf060986h","volume":"54","author":"M Leopoldini","year":"2006","unstructured":"Leopoldini M, Russo N, Chiodo S, Toscano M (2006) Iron chelation by the powerful antioxidant flavonoid quercetin. J Agric Food Chem 54(17):6343\u20136351. \n                    https:\/\/doi.org\/10.1021\/jf060986h","journal-title":"J Agric Food Chem"},{"key":"9878_CR137","doi-asserted-by":"publisher","first-page":"2986796","DOI":"10.1155\/2016\/2986796","volume":"2016","author":"LG Costa","year":"2016","unstructured":"Costa LG, Garrick JM, Roque PJ, Pellacani C (2016) Mechanisms of neuroprotection by quercetin: counteracting oxidative stress and more. Oxid Med Cell Longev 2016:2986796. \n                    https:\/\/doi.org\/10.1155\/2016\/2986796","journal-title":"Oxid Med Cell Longev"},{"key":"9878_CR138","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.201600692","author":"RD Horniblow","year":"2017","unstructured":"Horniblow RD, Henesy D, Iqbal TH, Tselepis C (2017) Modulation of iron transport, metabolism and reactive oxygen status by quercetin-iron complexes in vitro. Mol Nutr Food Res. \n                    https:\/\/doi.org\/10.1002\/mnfr.201600692","journal-title":"Mol Nutr Food Res"},{"issue":"3","key":"9878_CR139","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1021\/cn3001203","volume":"4","author":"PK Singh","year":"2013","unstructured":"Singh PK, Kotia V, Ghosh D, Mohite GM, Kumar A, Maji SK (2013) Curcumin modulates alpha-synuclein aggregation and toxicity. ACS Chem Neurosci 4(3):393\u2013407. \n                    https:\/\/doi.org\/10.1021\/cn3001203","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"9878_CR140","doi-asserted-by":"publisher","first-page":"e0128510","DOI":"10.1371\/journal.pone.0128510","volume":"10","author":"KJ Spinelli","year":"2015","unstructured":"Spinelli KJ, Osterberg VR, Meshul CK, Soumyanath A, Unni VK (2015) Curcumin treatment improves motor behavior in alpha-synuclein transgenic mice. PLoS ONE 10(6):e0128510. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0128510","journal-title":"PLoS ONE"},{"issue":"12","key":"9878_CR141","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1039\/c1np00051a","volume":"28","author":"SC Gupta","year":"2011","unstructured":"Gupta SC, Prasad S, Kim JH, Patchva S, Webb LJ, Priyadarsini IK, Aggarwal BB (2011) Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep 28(12):1937\u20131955. \n                    https:\/\/doi.org\/10.1039\/c1np00051a","journal-title":"Nat Prod Rep"},{"key":"9878_CR142","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.neulet.2013.01.007","volume":"536","author":"MC Dai","year":"2013","unstructured":"Dai MC, Zhong ZH, Sun YH, Sun QF, Wang YT, Yang GY, Bian LG (2013) Curcumin protects against iron induced neurotoxicity in primary cortical neurons by attenuating necroptosis. Neurosci Lett 536:41\u201346. \n                    https:\/\/doi.org\/10.1016\/j.neulet.2013.01.007","journal-title":"Neurosci Lett"},{"issue":"4","key":"9878_CR143","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3233\/JAD-2004-6403","volume":"6","author":"L Baum","year":"2004","unstructured":"Baum L, Ng A (2004) Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer\u2019s disease animal models. JAD 6(4):367\u2013377 (discussion 443\u2013369)","journal-title":"JAD"},{"issue":"5","key":"9878_CR144","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1021\/acs.jmedchem.6b00975","volume":"60","author":"KM Nelson","year":"2017","unstructured":"Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA (2017) The essential medicinal chemistry of curcumin. J Med Chem 60(5):1620\u20131637. \n                    https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00975","journal-title":"J Med Chem"},{"issue":"7","key":"9878_CR145","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1111\/j.1476-5381.2009.00295.x","volume":"157","author":"P Lu","year":"2009","unstructured":"Lu P, Mamiya T, Lu LL, Mouri A, Zou L, Nagai T, Hiramatsu M, Ikejima T, Nabeshima T (2009) Silibinin prevents amyloid beta peptide-induced memory impairment and oxidative stress in mice. Br J Pharmacol 157(7):1270\u20131277. \n                    https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00295.x","journal-title":"Br J Pharmacol"},{"issue":"2\u20133","key":"9878_CR146","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0162-0134(01)00198-2","volume":"85","author":"M Borsari","year":"2001","unstructured":"Borsari M, Gabbi C, Ghelfi F, Grandi R, Saladini M, Severi S, Borella F (2001) Silybin, a new iron-chelating agent. J Inorg Biochem 85(2\u20133):123\u2013129","journal-title":"J Inorg Biochem"},{"issue":"8","key":"9878_CR147","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1021\/acschemneuro.7b00110","volume":"8","author":"MFM Sciacca","year":"2017","unstructured":"Sciacca MFM, Romanucci V, Zarrelli A, Monaco I, Lolicato F, Spinella N, Galati C, Grasso G, D\u2019Urso L, Romeo M, Diomede L, Salmona M, Bongiorno C, Di Fabio G, La Rosa C, Milardi D (2017) Inhibition of abeta amyloid growth and toxicity by silybins: the crucial role of stereochemistry. ACS Chem Neurosci 8(8):1767\u20131778. \n                    https:\/\/doi.org\/10.1021\/acschemneuro.7b00110","journal-title":"ACS Chem Neurosci"},{"issue":"51","key":"9878_CR148","doi-asserted-by":"publisher","first-page":"89307","DOI":"10.18632\/oncotarget.19153","volume":"8","author":"H Zou","year":"2017","unstructured":"Zou H, Zhu XX, Zhang GB, Ma Y, Wu Y, Huang DS (2017) Silibinin: an old drug for hematological disorders. Oncotarget 8(51):89307\u201389314. \n                    https:\/\/doi.org\/10.18632\/oncotarget.19153","journal-title":"Oncotarget"},{"issue":"3","key":"9878_CR149","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3233\/JAD-2009-1068","volume":"17","author":"ML Hegde","year":"2009","unstructured":"Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P, Srinivas P, Sambamurti K, Rao KJ, Scancar J, Messori L, Zecca L, Zatta P (2009) Challenges associated with metal chelation therapy in Alzheimer\u2019s disease. JAD 17(3):457\u2013468. \n                    https:\/\/doi.org\/10.3233\/JAD-2009-1068","journal-title":"JAD"},{"key":"9878_CR150","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C, Praca C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 235:34\u201347. \n                    https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.044","journal-title":"J Control Release"},{"issue":"2","key":"9878_CR151","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/acs.biomac.6b01547","volume":"18","author":"N Wang","year":"2017","unstructured":"Wang N, Jin X, Guo D, Tong G, Zhu X (2017) Iron chelation nanoparticles with delayed saturation as an effective therapy for Parkinson disease. Biomacromol 18(2):461\u2013474. \n                    https:\/\/doi.org\/10.1021\/acs.biomac.6b01547","journal-title":"Biomacromol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-018-9878-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11030-018-9878-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-018-9878-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T19:10:40Z","timestamp":1570302640000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11030-018-9878-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,6]]},"references-count":151,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["9878"],"URL":"https:\/\/doi.org\/10.1007\/s11030-018-9878-4","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,6]]},"assertion":[{"value":"11 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}